NVP-BEZ235 is primarily used in cancer research due to its ability to inhibit both PI3K and mTOR pathways, which are crucial for cell growth and survival. It is often employed in preclinical studies to understand tumor biology and to evaluate its potential as a therapeutic agent. Researchers use it to explore its effects on various cancer types, including breast, prostate, glioblastoma, and gastrointestinal cancers, by targeting the dysregulated signaling pathways that drive tumor progression. Additionally, it is utilized in combination studies with other anticancer agents, such as chemotherapy and radiation, to assess synergistic effects, improve treatment efficacy, and reduce potential side effects. Its role in suppressing angiogenesis and metastasis further highlights its significance in oncology research.